Panacea Life Sciences Holdings, Inc.
Cash Flow Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.0M | $-9.1M | $-4.8M | $-5.2M | $-10.0M | $-4.3M | $-3.9M | $-1.6M |
| Depreciation & Amortization | — | — | — | — | — | $405.2K | $52.8K | $0 |
| Depreciation | $1.7M | $1.7M | $1.7M | $1.6M | $63.8K | $0 | — | — |
| Amortization | — | $61.4K | $61.4K | $61.4K | $828.5K | $0 | — | — |
| Stock-Based Compensation | — | — | — | $1.4M | $3.8M | $892.1K | $0 | $100.0K |
| Net Cash from Operating Activities | $-1.5M | $-2.4M | $-3.9M | $-7.6M | $-5.7M | $-465.8K | $-1.2M | $-891.0K |
| Investing Activities | ||||||||
| Capital Expenditures | $65.3K | $243.8K | $162.9K | $3.2M | $541.2K | $0 | — | $-1.3K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-65.3K | $-197.0K | $522.5K | $-3.1M | $-2.0M | $0 | $0 | $1.3K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.7M | $2.6M | $3.3M | $2.3M | $7.8M | $306.5K | $340.8K | $1.9M |
| Net Change in Cash | $94.0K | $-12.8K | $-64.6K | $6.7K | $16.4K | $-159.3K | $-894.1K | $1.1M |
| Free Cash Flow | $-1.6M | $-2.6M | $-4.1M | $-10.8M | $-6.3M | $-465.8K | — | $-889.7K |